Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Keros clears space for initial public offering
Medison Pharma and Partners Healthcare could be in line for exits after the haematological and musculoskeletal disorder therapy developer filed to raise $86.3m.
Imara implements IPO
Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.
Passage Bio amasses $248m for IPO close
The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.
Zentalis enters IPO stage
The Pharmaron-backed cancer therapy developer is targeting $100m in an initial public offering preceded by $162m in funding.
Ayala eyes $50m in initial public offering
Novartis and Harel are among the investors set to exit the cancer therapy developer, which also counts Bristol-Myers Squibb as a shareholder.
WeDoctor readies possible $1bn IPO
AIA,Tencent, Fosun, NWS Holdings and Tyan Home could exit the medical booking platform in an initial public offering valuing it at more than $10bn.
Oric originates IPO filing
The Taiho Ventures, Memorial Sloan and Hartford HealthCare Endowment-backed cancer drug developer has filed to raise up to $86.3m.
Cambricon clambers for public listing
Alibaba, Lenovo, Tuling Century and iFlytek are in line to exit the artificial intelligence chip producer, which was valued at $2.5bn as of 2018.

Other News

Accolade accelerates toward public markets
The Comcast, McKesson, Humana and Independence Health-backed digital health concierge developer has set an initial target of $100m for its proposed flotation.
DoorDash makes for public markets
Valued at $13bn in November, SoftBank-backed food delivery platform developer DoorDash has confidentially filed for an initial public offering.
Analysis: Revolution breaks out in $238m IPO
Oncology therapy developer Revolution Medicines went public giving an exit to pharmaceutical company Sanofi.
Imara introduces IPO filing
The sickle cell disease drug developer, which is backed by Pfizer Ventures and Lundbeckfonden Ventures, has filed for an $86.3m IPO.
Cashlez eyes IPO cash injection
The payment app developer, which counts Sumitomo among its investors, is seeking $7.3m in a flotation on the Indonesia Stock Exchange.
Revolution hits public markets in $238m IPO
The precision cancer therapy developer, which counts Sanofi as a significant shareholder, floated at the top of an upsized range and saw its price continue to rise post-IPO.

Editor's Picks fills up with $216m IPO
Financial automation software producer Bill is floating above its range as Fleetcor, Mastercard, Amex and a host of banks all scored exits.
Peloton pulls itself to billion-dollar IPO
Comcast NBCUniversal and Grace Beauty scored exits as Peloton Interactive floated at the top of its range to raise $1.16bn, getting a further $100m in a private placement.
Cloudflare clocks up $525m in IPO
Alphabet, Baidu, Microsoft and Qualcomm all notched up exits as the cloud services provider floated above a range that had already been increased.
Megvii makes for Hong Kong to IPO
The Alibaba and Foxconn-backed facial-recognition technology developer has filed for an offering that is reportedly set to raise $500m to $1bn.
test reg